Loss of treatment benefit when heroin-assisted treatment is stopped after 12 months

Demaret, Isabelle; Quertemont, Étienne; Litran, Géraldine; Magoga, Cécile; Deblire, Clémence; Dubois, Nathalie; Charlier, Corinne; Lemaître, André; Ansseau, Marc

doi:10.1016/j.jsat.2016.06.005

Cited by 11 publications

(12 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One article conducted a two-year follow-up of illicit drug use, HIV risk behavior, mental health, and physical health among participants from the Spanish PEPSA trial (Oviedo-Joekes et al, 2010d). One article evaluated treatment response three months following treatment discontinuation of the Belgian TADAM trial (Demaret et al, 2016), and one explored two-year outcomes for a non-randomized component of the Canadian NAOMI trial (Oviedo-Joekes et al, 2014a). Three articles assessed two-year outcomes for individuals from the German trial (Soyka et al, 2011;Verthein et al, 2008;Verthein et al, 2011).…”

Section: Longer-term Follow-up Of Hat Recipientsmentioning

confidence: 99%

“…Three articles assessed two-year outcomes for individuals from the German trial (Soyka et al, 2011;Verthein et al, 2008;Verthein et al, 2011). Only one identified article adopted an RCT design (Demaret et al, 2016).…”

Section: Longer-term Follow-up Of Hat Recipientsmentioning

confidence: 99%

“…RCT Evidence. Demaret et al (2016) conducted a follow-up study of the 12-month Belgian TADAM trial to examine the extent to which treatment benefits persisted following discontinuation of HAT. At the end of the trial period, patients in the experimental condition receiving supervised injectable or inhalable heroin were offered an alternative treatment.…”

Section: Longer-term Follow-up Of Hat Recipientsmentioning

confidence: 99%

See 2 more Smart Citations

Evidence on the Effectiveness of Heroin-Assisted Treatment

Smart¹

2018

View full text Add to dashboard Cite

This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited. Permission is given to duplicate this document for personal use only, as long as it is unaltered and complete. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial use. For information on reprint and linking permissions, please visit www.rand.org/pubs/permissions.html. The RAND Corporation is a research organization that develops solutions to public policy challenges to help make communities throughout the world safer and more secure, healthier and more prosperous. RAND is nonprofit, nonpartisan, and committed to the public interest. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.

show abstract

Section: Longer-term Follow-up Of Hat Recipientsmentioning

confidence: 99%

Section: Longer-term Follow-up Of Hat Recipientsmentioning

confidence: 99%

Section: Longer-term Follow-up Of Hat Recipientsmentioning

confidence: 99%

See 1 more Smart Citation

Evidence on the Effectiveness of Heroin-Assisted Treatment

Smart¹

2018

View full text Add to dashboard Cite

show abstract

“…32 However, a loss of treatment benefit (ie, an increase in street heroin use post-treatment to levels comparable with that of the control group) has been found repeatedly when prescription diacetylmorphine treatment was discontinued at a predetermined end date. 33,34 Thus, the authors of the Treatment Assisted by Diacetylmorphine (TADAM) study in Belgium, in line with World Health Organization recommendations for other OATs, recommend that supervised injection of diacetylmorphine be provided as an open-ended treatment. 33…”

Section: Opioid Agonist Treatmentmentioning

confidence: 99%

“…33,34 Thus, the authors of the Treatment Assisted by Diacetylmorphine (TADAM) study in Belgium, in line with World Health Organization recommendations for other OATs, recommend that supervised injection of diacetylmorphine be provided as an open-ended treatment. 33…”

Section: Opioid Agonist Treatmentmentioning

confidence: 99%

Nontraditional Alcohol and Opioid Agonist Treatment Interventions

Fairgrieve

Fairbairn

Samet

et al. 2018

Medical Clinics of North America

View full text Add to dashboard Cite

Despite the availability of effective medications and psychosocial interventions for the management of a substance use disorder, some individuals repeatedly fail the most aggressive treatment regimens. For such individuals, alternative treatment options exist seeking to mitigate the negative consequences of the use of harmful substances. Participation in a managed alcohol program, or the use of sustained-release oral morphine or injectable opioid agonist treatment or the creation of safe injecting facilities, are examples of such nonstandard approaches. This article reviews the available evidence of these treatment modalities.

show abstract

Injectable opioid agonist treatment: An evolutionary concept analysis

Haines

O’Byrne

2021

Research in Nursing & Health

View full text Add to dashboard Cite

Canada is currently in the midst of an overdose crisis. With new and innovative approaches desperately needed, injectable opioid agonist treatment (iOAT) should be considered as an integral treatment option to prevent even more fatalities. These programs provide injectable diacetylmorphine or hydromorphone to clients with severe opioid use disorders. Currently, they remain an under‐executed and under‐studied treatment modality. To better understand why this may be, we performed an evolutionary concept analysis as described by Rodgers. The attributes, antecedents, consequences, and surrogate terms of iOAT were unpacked and explored. Further, four themes were identified within the literature: (1) physical and mental health, (2) illicit drug use, (3) criminal behavior, and (4) ethical considerations. Recommendations surrounding the need for additional studies that focus on the perspectives of people who use opioids (PWUO), the necessity of nursing advocacy in iOAT, and the consideration of a changing illicit drug supply were explored. Further, theoretical analysis coupled with direct input from PWUO was discussed as a necessity to move forward with iOAT.

show abstract

Loss of treatment benefit when heroin-assisted treatment is stopped after 12 months

Cited by 11 publications

References 18 publications

Evidence on the Effectiveness of Heroin-Assisted Treatment

Evidence on the Effectiveness of Heroin-Assisted Treatment

Nontraditional Alcohol and Opioid Agonist Treatment Interventions

Injectable opioid agonist treatment: An evolutionary concept analysis

Contact Info

Product

Resources

About